Category Archives: Cell Therapy

FREEHOLD, N.J., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, today provided a clinical update on its chimeric antigen receptor (CAR) T-cell therapy and allogeneic mesenchymal stromal cell (MSC) therapy programs following successful completion of its Phase I clinical trial of AVA-001, the Companys leading CAR T-cell therapy candidate in development for patients with relapsed/refractory B-cell lymphoblastic leukemia (R/R B-ALL).

AVA-001

AVA-001 is a third generation CAR T-cell therapy which involves the 4-1BB (or CD28) co-stimulation signaling pathway, which we believe is designed to confer a more effective capacity for cancer cell-killing compared to older generation CAR T-cell therapies. As previously announced, Avalon has successfully completed a Phase I first-in-human clinical study of its leading CAR T-cell therapy candidate, AVA-001, for the treatment of R/R B-ALL (National Institute of Health clinical trial registration number: NCT03952923). Ninety percent of R/R B-ALL patients on trial achieved complete remission within one month of AVA-001 treatment and successfully proceeded to a curative-intent allogeneic bone marrow transplant.Accessory laboratory testing that accompanied this pilot clinical study has demonstrated evidence of enhancement in CAR T-cell persistence and protection against CAR T-cell exhaustion.

Given the positive results, Avalon is in the process of advancing AVA-001 CAR T-cell therapy for R/R B-ALL to the next phase of clinical development. In addition, Avalon is expanding its AVA-001 clinical trial to recruit patients with relapsed/refractory Non-Hodgkin lymphoma (R/R-NHL). This clinical paradigm of bridging CAR T-cell therapy to bone marrow transplant will provide a new therapeutic horizon with curative potential for patients with relapsed/refractory B-ALL, NHL and other hematologic malignancies.

CB-MSC-1

Avalons CB-MSC-1 is an innovative, allogeneic mesenchymal stromal cell (MSC) therapy candidate derived from human cord blood. Avalon plans to develop its MSC platform as a potential therapy for bone marrow transplant-related complications of acute graft-versus-host disease (aGVHD), and for acute respiratory distress syndrome (ARDS) associated with severe respiratory infection including SARS-CoV-2 virusthe causative agent of the ongoing global COVID-19 pandemic.

MSCs are typically isolated from the bone marrow, fat tissue and other tissue types and possess unique anti-inflammatory and immunomodulatory activities. These cells have the ability to suppress T-cell proliferation, cytokine secretion and regulate the balance of antibody-based and cell-based immune responses. MSCs can also tone down the abnormal release of antibodies from B-cells and cytokines from natural killer cells.

Avalon has completed pre-clinical studies and the standardized process development for its CB-MSC-1 cell therapy candidate, and anticipates initiation of a first-in-human clinical trial for aGVHD and ARDS during the fourth quarter of 2020. There is a substantial unmet need for the treatment of aGVHD and ARDS. Leveraging the Companys scientific and clinical expertise in cellular therapy and stem cell-derived exosome (ACTEX) technology, Avalon also plans to initiate a clinical trial of ACTEX-M, the clinical-grade exosomes derived from CB-MSC-1 as a candidate topical treatment for cutaneous aGVHD.

We are excited and encouraged by the clinical and technological progress we have made with these key cellular programs which are the cornerstone of Avalon, said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. We are committed to rapidly advancing these product candidates to address important unmet medical needs for patients, said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon.

About Avalon GloboCare Corp.

Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX), and regenerative therapeutics. For more information about Avalon GloboCare, please visit http://www.avalon-globocare.com.

For the latest updates on Avalon GloboCare's developments, please follow our twitter at @avalongc_avco

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

Contact Information:Avalon GloboCare Corp.4400 Route 9, Suite 3100Freehold, NJ 07728PR@Avalon-GloboCare.com

Investor Relations:Crescendo Communications, LLCTel: (212) 671-1020 Ext. 304avco@crescendo-ir.com

See the article here:
Avalon GloboCare Provides Clinical Updates on Its CAR-T Immuno-Oncology and Allogeneic Mesenchymal Stromal Cell (MSC) Therapy Programs Following...

Chicago, United States:Global Cell Freezing Media for Cell Therapy Market Report offers detailed research and analysis of key aspects of the global Cell Freezing Media for Cell Therapy market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Cell Freezing Media for Cell Therapy market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Cell Freezing Media for Cell Therapy market is carefully analyzed and researched about by the market analysts. The market analysts and researchers have done extensive analysis of the global Cell Freezing Media for Cell Therapy market with the help of research methodologies such as PESTLE and Porters Five Forces analysis.

Cell Freezing Media for Cell Therapy Market provided accurate and reliable market data and useful recommendations with an aim to help the players gain an insight into the overall present and future market scenario. The Cell Freezing Media for Cell Therapy report comprises in-depth study of the potential segments including product type, application, and end user and their contribution to the overall market size.

Key Companies/Manufacturers operating in the global Cell Freezing Media for Cell Therapy market include: BioLife Solutions, Thermo Fisher Scientific, Merck, GE Healthcare, Zenoaq, WAK-Chemie Medical, Biological Industries, Akron Biotechnology

Get Free PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart): https://www.reporthive.com/request_sample/2518121

Cell Freezing Media for Cell Therapy Market reports offers important insights which help the industry experts, product managers, CEOs, and business executives to draft their policies on various parameters including expansion, acquisition, and new product launch as well as analyzing and understanding the market trends.

Each segment of the global Cell Freezing Media for Cell Therapy market is extensively evaluated in the research study. The segmental analysis offered in the report pinpoints key opportunities available in the global Cell Freezing Media for Cell Therapy market through leading segments. The regional study of the global Cell Freezing Media for Cell Therapy market included in the report helps readers to gain a sound understanding of the development of different geographical markets in recent years and also going forth. We have provided a detailed study on the critical dynamics of the global Cell Freezing Media for Cell Therapy market, which include the market influence and market effect factors, drivers, challenges, restraints, trends, and prospects. The research study also includes other types of analysis such as qualitative and quantitative.

Regional analysis covers:

Key questions answered in the report:

* What is the growth potential of the Cell Freezing Media for Cell Therapy market?

* Which product segment will grab a lions share?

* Which regional market will emerge as a frontrunner in the coming years?

* Which application segment will grow at a robust rate?

* What are the growth opportunities that may emerge in the Cell Freezing Media for Cell Therapy industry in the years to come?

* What are the key challenges that the global Cell Freezing Media for Cell Therapy market may face in the future?

* Which are the leading companies in the global Cell Freezing Media for Cell Therapy market?

* Which are the key trends positively impacting the market growth?

* Which are the growth strategies considered by the players to sustain hold in the global Cell Freezing Media for Cell Therapy market?

>>>Get Full Customize report or for any Special Discount [emailprotected] https://www.reporthive.com/request_customization/2518121

Why Report Hive Research:

Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc.

Contact Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

Read the original post:
Corona Impact On Cell Freezing Media for Cell Therapy Market Driving Factor, Manufacturers And Analysis By 2026| BioLife Solutions, Thermo Fisher...

Cell Therapy Market report puts across the idea of high-level analysis of major market segments and identification of opportunities. This information not only aids businesses in taking sound and proficient decisions but also helps decide the advertising, promotion, marketing and sales strategy more gainfully. Moreover, estimation of strategic options, suggestions of winning action plans and support to make critical bottom-line decisions is also provided by experienced and innovative industry experts. It supports in adjusting the production depending on the conditions of demand in the market which evades the wastage of goods. The market data analysed in this Cell Therapy Market report makes achieve the business goal and objective in predetermined time frame.

Few of the major competitors currently working in the global Cell Therapy market are:

JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc.; and Medipost and many more.

Get Free Sample Report @ https://www.adroitmarketresearch.com/contacts/request-sample/611

A large-scale Cell Therapy Market report is of great importance for better understanding of the market which leads to high business growth. This market report has a chapter on the global market and all its associated companies with their profiles, which gives valuable data related to their outlook in terms of finances, product portfolios, investment plans, and marketing and business strategies. Cell Therapy Market research report provides important and meaningful market insights for the business by taking into consideration various factors. Thoroughly analysed market segmentation aspect provides a clear idea about the product consumption based on several factors ranging from type, application, deployment model, end user to geographical region.

Global Cell Therapy market is set to witness a healthy CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the surging adoption of AI and IoT along with the involvement of Cell Therapy vendors

Regional Analysis Includes:

*Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)*Europe (Germany, France, UK, Russia, and Italy etc.)*North America (the United States, Mexico, and Canada.)*South America (Brazil, Argentina, Columbia, etc.)*The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Table and Figures Covered in This Report:*Cell Therapy Market Overview, Scope, Status, and Prospect*Cell Therapy Market Competition by Manufacturers*Cell Therapy Market Capacity, Production, Revenue (Value) by Region*Cell Therapy Market Supply (Production), Consumption, Export, Import by Region*Cell Therapy Market Production, Revenue (Value), Price Trend by Type*Cell Therapy Market Analysis by Application*Cell Therapy Market Manufacturing Cost Analysis*Cell Therapy Market Industry Effect Factors Analysis*Cell Therapy Market Forecast*Cell Therapy Market Research Findings and Conclusion

Access Detailed Report at https://www.adroitmarketresearch.com/industry-reports/cell-therapy-market

Global Cell Therapy Market is segmented based by type, application and region.

Based on Type, the Market has been segmented into:

By Use & Type Outlook, (Clinical-use,By Cell Therapy Type,,Non-stem Cell Therapies,Stem Cell Therapies,BM, Blood, & Umbilical Cord-derived Stem Cells,Adipose derived cells,Others), By Therapeutic Area, (Malignancies,Muscoskeletal Disorders,Autoimmune Disorders,Dermatology,Others,Research-use), By Therapy Type, (Allogenic Therapies,Autologous Therapies)

What are the Recent Development of the Market?

Cell Therapy Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to Cell Therapy Market.

Key Questions Answered:

*What is the size and CAGR of the global Cell Therapy Market?*What are the key driving factors of the most profitable regional market?*Which are the leading segments of the global market?*How will the global market advance in the coming years?*What are the main strategies adopted in the global market?*What is the nature of competition in the global market?*What growth impetus or acceleration market carries during the forecast period?*Which region may hit the highest market share in the coming era?*What trends, challenges, and barriers will impact the development and sizing of the market?

Still Any Query? Feel Free to Contact our Expert at https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/611

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Read more:
Cell Therapy Market -Industry Trends, Opportunities and Forecasts to Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2025 - The...

HOUSTON, Oct. 1, 2020 /PRNewswire/ -- FibroGenesis, the leading developer of fibroblast based therapeutic solutions for unmet medical needs has entered into a clinical collaboration agreement with Brazilian R4D Biotech.Holding the world's largest patent portfolio in the field of cell therapies using fibroblasts, FibroGenesis is expanding its ongoing clinical programs internationally. The partnership will pave the way for clinical studies of PneumoBlast in Brazil as a unique treatment of acute respiratory distress syndrome (ARDS) for patients affected by COVID-19, in parallel to clinical studies in the United States upon approval by the FDA.

Administration of PneumoBlast in pre-clinical and animal studies resulted in dramatic improvement of immunological signaling molecules, reducing concentrations of the inflammatory cytokines interleukin-1 beta, interleukin-6, interleukin-8, interleukin-17, interleukin-18, and Tumor Necrosis Factor alpha TNFa. Company scientists have also demonstrated that PneumoBlast has induced statistically significant reduction of lung fibrosis and lung scarring in COVID-19 infected animals, particularly when compared to more conventional treatments using bone marrow derived mesenchymal stem cells (BMSCs). Furthermore, recent data supports the potential benefits of PneumoBlast for preventing COVID-19 blood clotting. Both companies will collaborate on a clinical study design that meets the needs of Brazilian patients.

"As the scientific and medical community is discovering more about the biological and medical consequences of the COVID-19 infection, FibroGenesis is eager to contribute to the therapeutic cure options currently being created to fight this global war against this virus," commented Pete O'Heeron, Chief Executive Officer, FibroGenesis. "The collaboration with R4D Biotech is another strategic milestone that emphasizes our commitment to expand fibroblast research globally."

"The lab results which indicate our cell therapy approach possesses both therapeutic effects on animal models of the acute stage of COVID-19, and also benefits a cure for residual pathology seen in COVID-19 patients, has our research team extremely excited," said Thomas Ichim, Ph.D., Chief Scientific Officer, FibroGenesis.

"Technology transfer is at the core of this partnership," said Paulo Ferraz, BRICS/Emerging Markets Director of international fund Newstar Ventures and an advisor for FibroGenesis on this transaction. "R4D Biotech has access to sophisticated resources comprising research facilities and hospitals, and its talent pool includes scientific advisors who are recognized academics and distinguished members of the Brazilian Academy of Pharmaceutical Sciences. PneumoBlast clinical study will represent the first step in a long-term relationship designed to aid in the discovery of advanced therapeutic solutions for chronic medical needs."

About R4D Biotech:R4D Biotech is a Brazilian emerging company headquartered in the state of So Paulo focused on research and development for biotechnology and healthcare, with the mission of bringing disruptive technology innovation across all steps of clinical development in life sciences.

About FibroGenesis:Based in Houston, Texas, FibroGenesis is a regenerative medicine company developing an innovative solution for chronic disease treatment using human dermal fibroblasts. Currently, FibroGenesis holds 240+ U.S. and international issued patents/patents pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure, Colitis and Heart Failure. FibroGenesis represents the next generation of medical advancement in cell therapy.Visit http://www.Fibro-Genesis.com.

SOURCE FibroGenesis

http://www.Fibro-Genesis.com

View post:
FibroGenesis Expands Fight Against COVID-19 In Brazil with International Collaboration - PRNewswire

Sept. 30, 2020 11:05 UTC

SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)-- Sonoma Biotherapeutics, a privately held company developing regulatory T-cell (Treg) therapies for autoimmune and degenerative diseases, announced that it has raised an additional $30 million from investors in its Series A financing, bringing the total to $70 million. Investors participating in the round include Lyell Immunopharma, ARCH Venture Partners, 8VC, LifeForce Capital, Lilly Asia Ventures Biosciences, Octagon Capital, Alexandria Venture Investments, the JDRF T1D Fund and additional undisclosed investors.

Sonoma also announced three new appointments to the senior management team: Leonard Dragone, M.D., Ph.D., joins as chief medical officer; Sejal Hall, Ph.D., joins as vice president of portfolio, program and alliance management; and Susan Lacy, Ph.D., joins as vice president of discovery. They join an experienced team steeped in next-generation research, development and manufacturing capabilities in immunology, cell therapy and genetic engineering.

We have made significant progress in a short amount of time in our mission to move adoptive cell therapy beyond cancer and into other disease areas, including autoimmunity and neuroinflammation, said Co-Founder and CEO Jeffrey Bluestone, Ph.D. Our progress in applying cell therapy to reprogram the immune system to alter the course of disease has attracted the attention and the vision of talented scientists and drug developers, as well as proven investors.

This expansion of the Sonoma team and the Series A financing will enable Jeff and the rest of the organization to continue their great progress, said Dr. Rick Klausner, executive chairman of Lyell Immunopharma and chair of the Sonoma Biotherapeutics board of directors. They are well poised to drive the next generation of cell therapy forward to advance treatments and potentially cures for patients with significant unmet medical need.

About Treg Cell Therapy

The goal of Treg therapy is to restore a state of self-tolerance by halting harmful inflammatory responses in autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis, along with degenerative diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimers. Over 50 million Americans currently live with an autoimmune disease, and millions more with some form of degenerative disease. For many, existing therapies are ineffective at controlling their disease.

Treg cells have a clear role in many of these conditions. These cells natural ability to migrate to inflamed tissues and control harmful immune responses makes them ideal for treating a range of conditions. In addition, the ability to engineer Treg cells to target specific disease-causing antigens reduces the potential for unwanted systemic effects. The role of Treg cells in tissue maintenance and repair offers the potential for effective, durable and restorative treatments.

About Sonoma Biotherapeutics

Sonoma Biotherapeutics is a South San Francisco and Seattle-based company leading the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies. More information at http://www.sonomabio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200930005266/en/

View original post here:
Sonoma Biotherapeutics Expands Series A Financing to $70 Million and Appoints Key Executives to Advance Regulatory T-cell Therapies in Autoimmune and...

TheCAR-T Cell Therapy Marketresearch report thoroughly explains each and every aspect related to the Global CAR-T Cell Therapy Market, which facilitates the reports reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business.

The Global CAR-T Cell Therapy Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global CAR-T Cell Therapy market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the CAR-T Cell Therapy Market in each region. Various methodological tools are used to analyze the growth of the worldwide CAR-T Cell Therapy market.

Global CAR-T cell therapy market is set to witness a healthy CAGR of 46.35% in the forecast period of 2019- 2026. The report contains data of the base year 2018 and historic year 2017. Rising cases of cancer and rising demand for effective method to cure cancer are factor for the growth of this market.

Get Free Sample PDF (including COVID19 Impact Analysis) of CAR-T Cell Therapy Market[emailprotected] https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-car-t-cell-therapy-market&utm_source=&kA

Prominent Key Players Covered in the report:

Autolus., Bellicum Pharmaceuticals, Inc., Bluebird Inc., CELGENE CORPORATION, Cellectis, Celyad, Eureka Therapeutics, Fortress Biotech., Immune Therapeutics, Juno Therapeutics, Kite Pharma, Novartis AG, Sorrento Therapeutics, Inc., TILT Biotherapeutics, Ziopharm Oncology, Inc., TrakCel, Tmunity Therapeutics, Promab Biotechnologies, Poseida Therapeutics, Inc., Minerva Biotechnologies Corporation and others.

Major Regions as Follows:

A complete value chain of the global CAR-T Cell Therapy market is presented in the research report. It is associated with the review of the downstream and upstream components of the CAR-T Cell Therapy Market. The market is bifurcated on the basis of the categories of products and customer application segments. The market analysis demonstrates the expansion of each segment of the global CAR-T Cell Therapy market. The research report assists the user in taking a decisive step that will be a milestone in developing and expanding their businesses in the global CAR-T Cell Therapy market.

The Objectives of the CAR-T Cell Therapy Market Report:

How Does This Market Insights Help?

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=global-car-t-cell-therapy-market&utm_source=&KA

Market Dynamics:The CAR-T Cell Therapy report also demonstrates the scope of the various commercial possibilities over the coming years and the positive revenue forecasts in the years ahead. It also studies the key markets and mentions the various regions i.e. the geographical spread of the industry.

Why choose us:

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

In conclusion, the CAR-T Cell Therapy Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

COVID-19 Impact Analysis:

The report seeks to track the evolution of the market growth pathways and publish a medical crisis in an exclusive section publishing an analysis of the impact of COVID-19 on the CAR-T Cell Therapy market. The new analysis on COVID-19 pandemic provides a clear assessment of the impact on the CAR-T Cell Therapy market and the expected volatility of the market during the forecast period. Various factors that can affect the general dynamics of the CAR-T Cell Therapy market during the forecast period (2020-2026), including current trends, growth opportunities, limiting factors, etc., are discussed in detail in this market research.

Else, Place an Enquiry Before Buying CAR-T Cell Therapy Market: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-car-t-cell-therapy-market&utm_source=&KA

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

Visit link:
CAR-T Cell Therapy Market to See Booming Growth and Huge Profit in Near Future - The Daily Chronicle

SlateXpace (pronounced "Slate Space") is a CRB solution that breaks from conventional facility design by providing unparalleled flexibility, speed to market and budget control, allowing companies to quickly deliver multiple novel therapies to patients. Clients get a customizable, time and cost-efficient solution that accommodates rapidly evolving multi-modal pipelines while future-proofing their capital investments. They also get peace of mind as SlateXpace leverages the expertise and capabilities of a team that manages every detail end to end from facility fabrication and delivery, equipment selection and installation, to start-up, qualification and operator training.

The agility at the heart of SlateXpace's mission heralds a critical turning point in the story of advanced therapy medicinal product (ATMP) manufacturing. The 1980s biotech explosion, the advent of stainless-steel facilities, and the arrival of closed processing technology and eventually ballroom manufacturing concepts each ushered periods of uncomfortable adjustment followed soon by untapped potential. Today, biotechnology companies are navigating the next scientific breakthrough with the promises brought on by the rise of cell and gene therapy products. However, many operators remain constrained by technologies and processes ill-suited for a fast-shifting market.

SlateXpace seizes on that potential by giving clients full operational turnkey delivery, upfront cost and schedule confidence and infinite flexibility, allowing clients to capture new markets or take advantage of emerging technologies. Implementing SlateXpace facilities allows you to constantly transform and grow with your business to address rapidly evolving market demands.

Drawing on CRB's more than 35 years of life sciences experience, SlateXpace's unique suite-based platform moves ATMP manufacturing beyond off-the-shelf cleanroom boxes and into a new era that empowers clients to shift flexibly, quickly and seamlessly between therapies. Using SlateXpace, an operator could run a product campaign in one modality, decontaminate that space, swap out single-use and mobile equipment and run a new batch in the same space in a different modality all within a few weeks.

Modalities currently test-fitted for SlateXpace include vaccines, monoclonal antibodies (mAbs), viral vectors, plasmids, allogeneic cell therapies and autologous cell therapies as well as the potential to accommodate other future biotech modalities an "X" factor that can accommodate bespoke client designs, new technologies or unforeseen scientific breakthroughs.

"SlateXpace meets the market need for a truly essential and efficient facility design, one that makes many, highly-tailored processes possible for clients," said Ryan Schroeder, President of CRB. "We started SlateXpace with the goal of delivering a facility that would never be idle. Manufacturers have the means to rapidly shift their operations as technologies change, business expands, and patient needs evolve. That will minimize downtime and maximize growth, no matter what comes next."

"Whether it's an established biotech company or contract manufacturing organization (CMO) looking for maximum operational flexibility to support complex product combinations across their global network, or a startup company looking for scalability and cost control so they can focus on development, SlateXpace provides a holistic solution with unparalleled advantages over today's manufacturing environments" said Noel Maestre, Director of SlateXpace based in San Diego. "The term 'disruptive' gets thrown around a lot in our industry. But for our clients, SlateXpace is exactly that a game-changing turnkey facility that delivers the kind of flexibility once considered impossible for customized and novel processes."

To learn more about SlateXpace and how CRB can provide your business a future-proof facility beating all industry benchmarks for speed, flexibility and adaptability visit our website at http://www.slatexpace.com. We can also be found on LinkedInand Twitter.

About SlateXpace:

SlateXpaceTM (pronounced "Slate Space"), is a CRB forward-looking solution that provides configurable and equipment-agnostic facilities to the ever-adapting life sciences industry. It allows clients to rapidly shift operations as technologies, business objectives, and patient needs evolve. Find us at http://www.slatexpace.com and on social media.

About CRB:

CRB is a leading provider of sustainable engineering, architecture, construction and consulting solutions to the global life sciences and advanced technology industries. Our more than 1,300 employees provide best-in-class solutions that drive success and positive change for our clients, our people and our communities. CRB is a privately held company with a rich history of serving clients throughout the world, consistently striving for the highest standard of technical knowledge, creativity and execution.

MEDIA CONTACT INFORMATION:Chris Clark: 816-200-5234

SOURCE CRB

http://www.crbusa.com

Read the original post:
CRB's SlateXpace gives cell and gene therapy clients new flexibility, control over manufacturing needs to support highly complex product pipelines -...

This study offers a complete assessment of the industry, as it comprises statistically supported and industry-validated market data, facts, crucial insights, and historical data. It also contains forecasts predicted by using an appropriate set of methodologies to give accurate values. The market analysis offers information according to categories determined through market segmentation, which includes the type of product, geographies, and applications.

The worldwide T-Cell Therapy market growth analysis is offered for both regional and global markets including insights on business strategy, development trends, opportunity, and important regions developmental status.

Get a Sample Copy of This Report @ https://www.quincemarketinsights.com/request-sample-68017?utm_source=cdn/ly

COVID-19 Market Impact Analysis

As the outbreak of the Coronavirus, a pandemic has worsened, the operations of various industries have been temporarily halted temporarily. The pandemic has caused disruptions in almost every aspect of life. As the world struggles to combat the crisis, the market players fear of the unknown and uncertainties have toppled the global financial markets, resulting in volatile stock markets. The virus has changed the market scenario and this may have a long-lasting impact.

This study covers the supply chain analysis, which was evidently disrupted in the wake of the pandemic. The study on the T-Cell Therapy market size growth rate and future prospects in a changing world includes the procedures undertaken by corporations in response to the COVID-19 epidemic.

Major Features of the Market Study

market study Outlook:

The market study offers first-hand information from analysts with expert opinions, along with industry participants across the value chain. The market study offers a profound analysis of macro-economic indicators, market developments, and prevailing factors that are driving the segments growth. The market study also maps various factors that are benefiting the market in various geographies.

Insights on Market Study:

The market study also helps in understanding the Global T-Cell Therapy market dynamics and structure, by analyzing the market segments and by projecting the Global T-Cell Therapy market size. Financial position, competitive analysis of key players by product portfolio, price, type, regional presence, and growth strategies in the market offer valuable insights.

The market study also presents a comprehensive analysis of the Global T-Cell Therapy market including all the stakeholders of the industry. Internal and External factors that are influencing the industry either positively or negatively have been extensively analyzed, which will present a futuristic outlook of the market for the decision makers.

Segments in Market Study

The market study assesses the segments projected to register lucrative growth along with the leading segment of the market. The Global T-Cell Therapy market segmentation includes By Therapy (CAR T-Cell, Tumor Infiltrating Lymphocytes)By Indication (Hematologic Malignancies, Solid Tumors) The study also defines market sizes for various segments in the previous years and also projects market forecast and values up to the next five years.

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-68017?utm_source=cdn/ly

Regional Evaluation:

Geographically, the global T-Cell Therapy market is segmented into several regions, namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific Excluding Japan, Japan, Middle East, and Africa.

Prominent Players:

The upcoming opportunities due to research and development activities will open new avenues for companies. The major T-Cell Therapy market producers studied in the report are Novartis AG; Gilead Sciences; bluebird bio; TCR2 Therapeutics Inc.; Sorrento Therapeutics; and Fate Therapeutics.

Key Highlights

The complete study for the T-Cell Therapy market gives you an analysis of market size, share, growth, marketplace, technological innovations, trends, cost structure, revenue, and statistical and comprehensive data of the global market. Besides providing information regarding the key players in the market, the study also recalibrates the impact of macroeconomic and microeconomic factors that have the potential to impact the growth of the market.

If You Have Any Query, Ask Our Experts @ https://www.quincemarketinsights.com/ enquiry-before-buying/enquiry-before-buying-68017?utm_source=cdn/ly

About Us:

With industry expertise, QMI offers multifaceted insights on various aspects of the market in numerous domains. We help companies in evaluating market conditions to build an efficient strategy that offers an edge over their competitors. In our reports, we offer trustable insights for gaining market access with studies that provide leading business solutions.

Contact Us:

Quince Market Insights

Office No- A109,

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email:[emailprotected]

Web: http://www.quincemarketinsights.com

See original here:
T-Cell Therapy Market 2020: key Vendors, Trends, Analysis, Segmentation, Forecast to 2025 - Crypto Daily

The global platelet rich plasma & stem cell alopecia treatment market report comprises an elaborate executive summary, including a snapshot that provides information on various segments of the market. It also provides information and data analysis of the global market with respect to segments based on treatment, indication, end-user, and region. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. Additionally, the section comprises a competitive matrix and profiles of key market players, along with business overview, to project the competitive landscape of the market. The section also provides presence of key players working in the development of stem cell and platelet rich pharmaceutical products, thereby presenting a thorough analysis of the overall competitive scenario in the global platelet rich plasma & stem cell alopecia treatment market.

This report analyzes the current and future scenario of the global platelet rich plasma & stem cell alopecia treatment market for the period 2018 to 2026. Rise in awareness about platelet rich plasma therapies and stem cell therapies, increase in funding for alopecia treatment research and stem cell research, and increase in the incidence of autoimmune hair loss disorders are likely to be major drivers of the global platelet rich plasma & stem cell alopecia treatment market during the forecast period.

Request Brochure for Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=55800

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment market Witness Most Promising Rise in Demand

The global platelet rich plasma & stem cell alopecia treatment market is expected to reach a value of approximately US$ 450.5 Mn by the end of 2026, expanding at a high single digit CAGR during the forecast period. Factors such as increase in demand for accurate and prompt treatment of alopecia and advancements in platelet rich plasma and stem cell therapies that have revolutionized the diagnostic science are likely to boost the market. Moreover, a rise in awareness about platelet rich plasma therapies and stem cell therapies is expected to drive the global market during the forecast period.

Increased awareness has driven demand for platelet rich plasma therapy & stem cell therapy in the past few years in countries such as Japan, India, Brazil, and Russia and developed regions such as North America and Europe. Additionally, private players are actively promoting the advantages of treatment of alopecia with stem cell therapy across the globe. A rise in the incidence rates of autoimmune hair loss disorders such as alopecia is estimated to boost the platelet rich plasma & stem cell alopecia treatment market. According to the Journal of Clinical, Cosmetic, and Investigational Dermatology, 2015, the lifetime incidence rate of alopecia areata is approximately 2% worldwide. This is expected to propel the market. However, a lack of treatment approval and high cost of alopecia treatment are likely to hinder the growth of platelet rich plasma & stem cell alopecia treatment market.

Request for Analysis of COVID19 Impact on Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=55800

Based on treatment, the global platelet rich plasma & stem cell alopecia treatment market has been segmented into platelet rich plasma therapy and stem cell therapy. The stem cell therapy segment has been further classified into bone marrow treatment and adipose treatment. In terms of indication, the global platelet rich plasma & stem cell alopecia treatment market has been classified into androgenic alopecia, congenital alopecia, cicatricial or scarring alopecia and others. Based on end-user, the global platelet rich plasma & stem cell alopecia treatment market has been divided into hospitals, dermatology clinics, and others. The market size and forecast for each of these segments have been provided for the period 2018 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2017 as the base year.

Key Players of Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Report:

Major players operating in the global platelet rich plasma & stem cell alopecia treatment market include Kerastem, Eclipse, Regen Lab SA, Stemcell Technologies, Inc., RepliCel Life Sciences, Histogen, Inc., and Glofinn Oy. Key players are focused on research & development of alopecia treatment by investing in platelet rich plasma & stem cell alopecia therapies. Mergers & acquisitions, collaborations, and partnerships are helping companies expand their footprint and further develop effective treatments for alopecia.

Buy Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Report

https://www.transparencymarketresearch.com/checkout.php?rep_id=55800&ltype=S

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

More:
Platelet Rich Plasma and Stem Cell Alopecia Treatment Market -Key Players, Size, Growth, Incredible Potential, and Stagnant Progress According to New...

ReNeuron, the UK based, clinical-stage stem cell therapeutics company, announced that new data relating to its CTX stem cell platform will be presented today at the 27th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT).

Get a complete list of the presentations,here.

Dr. Steve Pells, Principal Investigator at ReNeuron, will present new data showing the phenotypic stability and scalability of a mesenchymal stem cell line derived from the companys proprietary, conditionally immortalized, human neural stem cell line (CTX) following re-programming to a pluripotent state. The new data being presented today show for the first time that these CTX-iPSCs (induced pluripotent stem cells) can indeed be differentiated along different cell lineages to generate, for example, mesenchymal stem cell lines.

Further, the mesenchymal stem cell lines generated can be grown at scale by virtue of the companys conditional immortalization technology, enabling the efficient production of clinical-grade cell therapy candidates.

Cell and Gene Therapy Market:

Cell and gene therapies have garnered a lot of traction from several big pharma players and new drug developers in recent years. In fact, as per the Alliance of Regenerative Medicines recent findings, there has been more than 75% year on year increment in funding to support the development of various cell and gene therapies. With over 2,600 clinical trials registered to date, cell and gene therapies are playing in a league of their own.

For further information, check out the report here

Read more insights at

Roots Analysis Leaders in Pharmaceutical & Biotechnology Market Research

You may also be interested in the following titles:

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If youd like help with your growing business needs, get in touch at [emailprotected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[emailprotected]

Read the original here:
Cell and Gene Therapy Technology Update: ReNeuron Presents Positive Data | Roots Analysis - Crypto Daily